Roche's Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer

Roche's Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer

Submitted by admin on March 8, 2019 - 2:27pm
Source: 
First Word Pharma
News Tags: 
Roche
Genentech
FDA
Tecentriq
triple negative breast cancer
Headline: 
Roche's Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer
snippet: 

Roche's Genentech unit on Friday announced that the FDA granted accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy for use in adults with PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.

Do Not Allow Advertisers to Use My Personal information